Efficacy of anakinra in refractory adult-onset still's disease multicenter study of 41 patients and literature review

Medicine (United States)

Volumn 94, Issue 39, 2015, Pages e1554-

  Ortiz Sanjuán, Francisco ^a   Blanco, Ricardo ^a   Riancho Zarrabeitia, Leyre ^a   Castañeda, Santos ^b   Olivé, Alejandro ^c   Riveros, Anne ^c   Velloso Feijoo, María L ^d   Narváez, Javier ^e   Jiménez Moleón, Inmaculada ^f   Maiz Alonso, Olga ^g   Ordóñez, Carmen ^h   Bernal, José A ⁱ   Hernández, María V ^j   Sifuentes Giraldo, Walter A ^k   Gómez Arango, Catalina ^l   Galíndez Agirregoikoa, Eva ^l   Blanco Madrigal, Juan ^l   Ortiz Santamaria, Vera ^m   Del Blanco Barnusell, Jordi ⁿ   De Dios, Juan R ^o   Moreno, Mireia ^p   Fiter, Jordi ^q   De Los Riscos, Marina ^r   Carreira, Patricia ^r   Rodriguez Valls, María J ^s   González Vela, M Carmen ^a   Calvo Río, Vanesa ^a   Loricera, Javier ^a   Palmou Fontana, Natalia ^a   Pina, Trinitario ^a   Llorca, Javier ^t,u   González Gay, Miguel A ^a   more..

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^b HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^c HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^d HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^e HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^f HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^g HOSPITAL DONOSTIA   (Spain)

^h HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

ⁱ Neurology Service   (Spain)

^j HOSPITAL CLÍNIC   (Spain)

^k HOSPITAL RAMÓN Y CAJAL   (Spain)

^l HOSPITAL DE BASURTO   (Spain)

^m HOSPITAL GENERAL DE GRANOLLERS   (Spain)

ⁿ H Sant Jaume   (Spain)

^o HU Álava   (Spain)

^p Parc Taulí Health Corporation   (Spain)

^q HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^r HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^s HOSPITAL DE JEREZ   (Spain)

^t UNIVERSITY OF CANTABRIA   (Spain)

^u CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; CREATININE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ETANERCEPT; FERRITIN; HEMOGLOBIN; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLATE MOFETIL; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SALAZOSULFAPYRIDINE; TOCILIZUMAB; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ADOLESCENT; ADULT; ADULT ONSET STILL DISEASE; ANEMIA; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE ACTIVITY; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FERRITIN BLOOD LEVEL; FEVER; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HEPATOMEGALY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LEUKOPENIA; LYMPHADENOPATHY; MALE; MULTICENTER STUDY (TOPIC); MYOPATHY; PERICARDITIS; PLEURISY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REFRACTORY ADULT ONSET STILL DISEASE; RESPIRATORY TRACT INFECTION; RETROSPECTIVE STUDY; SKIN MANIFESTATION; SPLENOMEGALY; URINARY TRACT INFECTION; CLINICAL TRIAL; COMBINATION DRUG THERAPY; MIDDLE AGED; MULTICENTER STUDY; STILL'S DISEASE, ADULT-ONSET;

ADULT; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MALE; MIDDLE AGED; PREDNISONE; RETROSPECTIVE STUDIES; STILL'S DISEASE, ADULT-ONSET;

EID: 84943195545     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000001554     Document Type: Article

References (21)

1. Riera E, Olive A, Narvaez J, et al. Adult onset Still's disease: review of 41 cases. Clin Exp Rheumatol. 2011;29:331-336.
2. Pouchot J, Sampalis JS, Beaudet F, et al. Adult Still's disease: manifestations, disease course, and outcome in 62 patients. Medicine (Baltimore). 1991;70:118-136.
3. Fitzgerald AA, Leclercq SA, Yan A, et al. Rapid responses to anakinra in patients with refractory adult-onset Still's disease. Arthritis Rheum. 2005;52:1794-1803.
4. Kotter I, Wacker A, Koch S, et al. Anakinra in patients with treatment-resistant adult-onset Still's disease: four case reports with serial cytokine measurements and a review of the literature. Semin Arthritis Rheum. 2007;37:189-197.
5. Hoshino T, Ohta A, Yang D, et al. Elevated serum interleukin 6, interferon-gamma, and tumor necrosis factor-Alpha levels in patients with adult Still's disease. J Rheumatol. 1998;25:396-398.
6. Fujii T, Nojima T, Yasuoka H, et al. Cytokine and immunogenetic profiles in Japanese patients with adult Still's disease. Association with chronic articular disease. Rheumatology (Oxford). 2001;40:1398-1404.
7. Giampietro C, Fautrel B. Anti-interleukin-1 agents in adult onset Still's disease. Int J Inflam. 2012;2012:317820.
8. Lequerre T, Quartier P, Rosellini D, et al. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis. 2008;67:302-308.
9. Naumann L, Feist E, Natusch A, et al. IL1-receptor antagonist anakinra provides long-lasting efficacy in the treatment of refractory adult-onset Still's disease. Ann Rheum Dis. 2010;69:466-467.
10. Laskari K, Tzioufas AG, Moutsopoulos HM. Efficacy and long-term follow-up of IL-1R inhibitor anakinra in adults with Still's disease: a case-series study. Arthritis Res Ther. 2011;13:R91.
11. Giampietro C, Ridene M, Lequerre T, et al. Anakinra in adult-onset Still's disease: long-term treatment in patients resistant to conventional therapy. Arthritis Care Res (Hoboken). 2013;65:822-826.
12. Nordstrom D, Knight A, Luukkainen R, et al. Beneficial effect of interleukin 1 inhibition with anakinra in adult-onset Still's disease. An open, randomized, multicenter study. J Rheumatol. 2012;39:2008-2011.
13. Yamaguchi M, Ohta A, Tsunematsu T, et al. Preliminary criteria for classification of adult Still's disease. J Rheumatol. 1992;19: 424-430.
14. Ortiz-Sanjuan F, Blanco R, Calvo-Rio V, et al. Efficacy of tocilizumab in conventional treatment-refractory adult-onset Still's disease: multicenter retrospective open-label study of thirty-four patients. Arthritis Rheumatol. 2014;66:1659-1665.
15. Cohen SB, Moreland LW, Cush JJ, et al. A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Ann Rheum Dis. 2004;63:1062-1068.
16. Quartier P, Allantaz F, Cimaz R, et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis. 2011;70:747-754.
17. Kalliolias GD, Georgiou PE, Antonopoulos IA, et al. Anakinra treatment in patients with adult-onset Still's disease is fast, effective, safe and steroid sparing: experience from an uncontrolled trial. Ann Rheum Dis. 2007;66:842-843.
18. Cavalli G, Franchini S, Aiello P, et al. Efficacy and safety of biological agents in adult-onset Still's disease. Scand J Rheumatol. 2015:1-6.
19. Hong D, Yang Z, Han S, et al. Interleukin 1 inhibition with anakinra in adult-onset Still disease: a meta-Analysis of its efficacy and safety. Drug Des Devel Ther. 2014;8:2345-2357.
20. Iliou C, Papagoras C, Tsifetaki N, et al. Adult-onset Still's disease: clinical, serological and therapeutic considerations. Clin Exp Rheumatol. 2013;31:47-52.
21. Gerfaud-Valentin M, Maucort-Boulch D, Hot A, et al. Adult-onset still disease: manifestations, treatment, outcome, and prognostic factors in 57 patients. Medicine (Baltimore). 2014;93:91-99.